Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Mirum Pharmaceuticals (Nasdaq: MIRM), a biopharmaceutical company specializing in rare and orphan diseases, has announced its participation in several upcoming investor conferences in September 2024. These include:

• Morgan Stanley 22nd Annual Global Healthcare Conference (Sept 4, 8:30 a.m. ET)
• H.C. Wainwright 26th Annual Global Investment Conference (Sept 10)
• Baird 2024 Global Healthcare Conference (Sept 11)
• 2024 Cantor Global Healthcare Conference (Sept 18, 1:55 p.m. ET)

Investors can find webcast links and additional information in the Investors and Media section of Mirum's corporate website.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:

• Morgan Stanley 22^nd Annual Global Healthcare Conference
  • Company presentation - Wednesday, September 4^th starting at 8:30 a.m. ET
• H.C. Wainwright 26^th Annual Global Investment Conference on Tuesday, September 10^th
• Baird 2024 Global Healthcare Conference on Wednesday, September 11^th
• 2024 Cantor Global Healthcare Conference
  • Company presentation - Wednesday, September 18^th starting at 1:55 p.m. ET

Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum’s late-stage pipeline includes three investigational treatments for debilitating liver diseases. LIVMARLI is currently being evaluated in the Phase 3 EXPAND study in additional settings of cholestatic pruritus. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, chenodiol, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023. Mirum has submitted a new drug application with the FDA for the approval of chenodiol to treat CTX in the U.S.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240828258017/en/

Investor Contacts:

Andrew McKibben

ir@mirumpharma.com

Media Contact:

Erin Murphy

media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

What investor conferences will Mirum Pharmaceuticals (MIRM) attend in September 2024?

Mirum Pharmaceuticals will participate in four investor conferences in September 2024: Morgan Stanley Global Healthcare Conference, H.C. Wainwright Global Investment Conference, Baird Global Healthcare Conference, and Cantor Global Healthcare Conference.

When is Mirum Pharmaceuticals (MIRM) presenting at the Morgan Stanley Global Healthcare Conference?

Mirum Pharmaceuticals is scheduled to present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th, 2024, starting at 8:30 a.m. ET.

Where can investors find webcast links for Mirum Pharmaceuticals' (MIRM) conference presentations?

Investors can find webcast links and additional information for Mirum Pharmaceuticals' conference presentations in the Investors and Media section of the company's corporate website.

What is Mirum Pharmaceuticals' (MIRM) focus as a biopharmaceutical company?

Mirum Pharmaceuticals focuses on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases.